O-19: GLP-1 receptor agonists in Wolfram syndrome: clinical experience from a pediatric case series
Hormone Research in Paediatrics · 04.11.2026 · 99 (Supplement_4)
DOI: 10.1159/hrp/adaag020.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone Research in Paediatrics, online erschienen am 04.11.2026. Verfasst von P Bruzzi und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Wolfram syndrome type 1 (WS1) is a rare autosomal recessive neurodegenerative disorder due to WFS1 variants. It classically includes non-autoimmune insulin-dependent diabetes, optic atrophy, diabetes insipidus and deafness, but shows marked phenotypic heterogeneity. GLP-1 receptor agonists (GLP-1RAs) may reduce ER stress and exert anti-apoptotic effects, suggesting a disease-modifying role.
Objectives
To describe clinical variability and assess the impact of GLP-1RA therapy in pediatric WS1 Methods We report 3 female adolescents with genetically confirmed WS1 followed at our center Results Patients 1 and 2 (sisters; compound heterozygous variants c.2020G>A, c.316-2A>G) developed childhood-onset non-autoimmune diabetes with preserved β-cell function. Patient 1 showed a mild disease onset (isolated glycosuria, intermittent hyperglycemia), making the progression consistent with a MODY-like pattern. Both patients later experienced metabolic control deterioration and extra-pancreatic features began slightly to emerge (renal cysts, steatosis, initial optic atrophy). GLP-1RA therapy, introduced in both patients, reduced insulin requirement (0.94–0.84 to 0.44 IU/kg/day) and markedly improved metabolic control [time in range (TIR) 33% to 92% and 28% to 83% within 1 month, respectively]. Patient 3 (homozygous variant c.2099G>A; c.2141_2164dup) had a more severe clinical course, with diabetes onset at 5 years (autoantibody-negative; C-peptide 0.2 ng/ml) and early multisystem involvement (optic atrophy, hearing loss, growth hormone deficiency, attention deficit disorder). GLP-1RA improved TIR (74% to 86%) and reduced insulin requirement (1.31 to 0.72 IU/kg/day).
Conclusions
This case series highlights marked WS1 phenotypic variability, even within families, supporting genotype–phenotype correlations and the need to consider WS1 in the differential diagnosis of atypical non-autoimmune diabetes. GLP-1RAs show promising metabolic benefits and may represent an emerging strategy targeting ER stress–related neurodegeneration.
Zitieren
APA
Bruzzi, P., Candia, F., Villanova, M., Frontino, G., Madeo, S. F., Lucaccioni, L., Trevisani, V., Iughetti, L., & Predieri, B. (2026). O-19: GLP-1 receptor agonists in Wolfram syndrome: clinical experience from a pediatric case series. Hormone Research in Paediatrics, 99(Supplement_4). https://doi.org/10.1159/hrp/adaag020.019
Vancouver
Bruzzi P, Candia F, Villanova M, Frontino G, Madeo SF, Lucaccioni L, et al. O-19: GLP-1 receptor agonists in Wolfram syndrome: clinical experience from a pediatric case series. Hormone Research in Paediatrics. 2026;99(Supplement_4). doi:10.1159/hrp/adaag020.019
BibTeX
@article{Bruzzi2026,
author = {Bruzzi, P and Candia, F and Villanova, M and Frontino, G and Madeo, S F and Lucaccioni, L and Trevisani, V and Iughetti, L and Predieri, B},
title = {O-19: GLP-1 receptor agonists in Wolfram syndrome: clinical experience from a pediatric case series},
journal = {Hormone Research in Paediatrics},
year = {2026},
volume = {99},
number = {Supplement_4},
doi = {10.1159/hrp/adaag020.019}
}
EUVIMED